Medicus Pharma LTD 8-K filings

Medicus Pharma Ltd. has entered into a note purchase agreement with Streeterville Capital, LLC, securing $22.86 million through two secured promissory notes to fund clinical development and business initiatives.

Medicus Pharma has increased its at-the-market equity offering program to $50 million while disclosing a Nasdaq minimum bid price deficiency notice.

Medicus Pharma Ltd. completed multiple unregistered sales of common shares to YA II PN, Ltd. under a Standby Equity Purchase Agreement, raising approximately $3.8 million.

Medicus Pharma Ltd. has established an at-the-market equity program to potentially raise up to $15.3 million through common share sales.

Medicus Pharma Ltd. announced a warrant inducement agreement to raise approximately $5.1 million through the exercise of existing warrants, coupled with the issuance of new warrants.

Medicus Pharma Ltd. announced the appointment of Carolyn Bonner as Chief Financial Officer, alongside significant progress in its clinical development programs and strategic initiatives.

Medicus Pharma Ltd. announced its third-quarter 2025 financial and operating results, highlighting significant progress in its SkinJect and Teverelix clinical development programs and strategic corporate expansions.

Medicus Pharma Ltd. completed a series of unregistered equity sales to Yorkville, raising over $2.5 million, with proceeds partially used to prepay a debenture.

Medicus Pharma Ltd. announced an $8 million non-dilutive debenture financing to accelerate the clinical development of Teverelix for prostate cancer and acute urinary retention, with net proceeds of $5.7 million after refinancing existing debt and fees.

Medicus Pharma Ltd. announced that its Chief Financial Officer, James Quinlan, is taking a medical leave of absence, with President Carolyn Bonner stepping in as Acting CFO.

Medicus Pharma Ltd. has finalized its acquisition of clinical-stage biotech Antev Ltd., integrating Teverelix, a next-generation GnRH antagonist, into its development pipeline.

Medicus Pharma reports progress in its D-MNA clinical trials, secures significant financing, and pursues strategic acquisitions and collaborations while increasing its net loss in Q2 2025.

Medicus Pharma Ltd. and Helix Nanotechnologies Inc. announced a non-binding memorandum of understanding to co-develop thermostable mRNA vaccines using their combined proprietary technologies.

Medicus Pharma Ltd. has appointed Deloitte LLP as its exclusive lead financial advisor to seek partners for an out-licensing transaction of its Doxorubicin Microneedle Array (D-MNA) for Basal Cell Carcinoma treatment.

Medicus Pharma Ltd. shareholders approved all proposals at the 2025 Annual and Special Meeting, including the election of new board members, a significant equity issuance mechanism, and corporate governance amendments.

Medicus Pharma Ltd. announced an inducement offer resulting in the exercise of existing warrants for $3.75 million and the issuance of new warrants, alongside an additional $1.521 million raised through equity sales, to fund clinical trials and the Antev Limited acquisition.

Medicus Pharma Ltd. has completed the acquisition of Antev Limited, gaining full ownership of the Phase 2b-ready drug candidate Teverelix and committing to significant milestone payments tied to its clinical development and FDA approvals.

Medicus Pharma Ltd. has entered into a definitive agreement to acquire Antev Ltd., a clinical-stage biotech company, gaining Teverelix, a next-generation GnRH antagonist, for prostate cancer and acute urinary retention, alongside its existing dermatology pipeline.

Medicus Pharma Ltd. announced the appointment of Andrew Smith as Chief Operating Officer, provided updates on its Phase 2 clinical studies for basal cell carcinoma, and confirmed its binding letter of intent to acquire UK-based Antev Ltd.

Medicus Pharma Ltd. announced the completion of its previously disclosed debenture financing agreement with YA II PN, Ltd., securing the final $2.5 million tranche of a total $5 million principal amount.

Medicus Pharma Ltd. has dismissed its independent auditor EisnerAmper LLP and engaged KPMG LLP, following EisnerAmper's report raising substantial doubt about the company's ability to continue as a going concern and identifying material weaknesses in internal controls.

Medicus Pharma Ltd. successfully closed a $7.0 million public offering, with proceeds earmarked primarily for advancing its basal cell carcinoma clinical trials and other strategic initiatives.

Medicus Pharma Ltd. enters into a securities purchase agreement with YA II PN, Ltd. for debentures up to $5 million, with an initial tranche of $1.25 million funded.

Medicus Pharma Ltd. has entered into a binding letter of intent to acquire Antev Ltd., a clinical-stage biotech company, in a share exchange transaction valued at approximately \$75 million.

Medicus Pharma Ltd. has cancelled its previously announced annual and special meeting of shareholders and the associated record date.

Medicus Pharma Ltd. announces its annual and special meeting of shareholders to be held on May 22, 2025, with a record date of April 22, 2025.

Medicus Pharma Ltd. successfully closed a $4.2 million Regulation A offering to advance its clinical trials for basal cell carcinoma treatment.

Medicus Pharma Ltd. enters into a Standby Equity Purchase Agreement with YA II PN, LTD for up to $15 million and announces its intention to voluntarily delist from the TSX Venture Exchange.